PubRank

Jørgen Jespersen

Author PubWeight™ 40.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012 2.41
2 Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014 2.29
3 A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol 2006 2.09
4 Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007 1.73
5 A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost 2009 1.46
6 Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004 1.40
7 Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem 2006 1.40
8 [Postmenopausal hormone replacement therapy--is there a cause of worry?]. Ugeskr Laeger 2002 1.39
9 Long-term effects on haemostatic variables of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals. Br J Nutr 2010 1.38
10 Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013 1.36
11 Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012 1.13
12 Associations between aortic calcification and components of body composition in elderly men. Obesity (Silver Spring) 2006 1.11
13 Influence of the VKORC1 3730 G > A polymorphism on warfarin dose. Eur J Clin Pharmacol 2012 1.07
14 Analytical and clinical validation of a new point-of-care testing system for determination of D-Dimer in human blood. Thromb Res 2010 1.06
15 General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013 0.99
16 Factor VII-activating protease in patients with acute deep venous thrombosis. Thromb Res 2008 0.97
17 Simplified method for international normalized ratio (INR) derivation based on the prothrombin time/INR line: an international study. Clin Chem 2010 0.93
18 European concerted action on anticoagulation. Use of plasma samples to derive international sensitivity index for whole-blood prothrombin time monitors. Clin Chem 2002 0.88
19 Evaluation of European Concerted Action on Anticoagulation lyophilized plasmas for INR derivation using the PT/INR line. Am J Clin Pathol 2011 0.88
20 A reference system approach to future standardization of laboratory tests for hemostasis. A position paper of the Joint Committee of the IFCC Scientific Division and the ISTH Scientific and Standardization Committee. Thromb Haemost 2002 0.87
21 Multivariate analysis of the relation between diet and warfarin dose. Eur J Clin Pharmacol 2011 0.87
22 Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005 0.83
23 Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2016 0.83
24 Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. Thromb Haemost 2002 0.82
25 Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am J Obstet Gynecol 2002 0.81
26 Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004 0.81
27 Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis. Blood Coagul Fibrinolysis 2008 0.79
28 A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. Br J Haematol 2008 0.79
29 The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thromb Res 2012 0.79
30 Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic. Eur J Clin Pharmacol 2011 0.78
31 Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002 0.78
32 Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution. Blood Coagul Fibrinolysis 2008 0.78
33 A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. Hum Reprod 2007 0.78
34 Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thromb Haemost 2007 0.77
35 Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study. Hum Reprod 2003 0.77
36 Effects on markers of inflammation and endothelial cell function of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals. Br J Nutr 2011 0.76
37 Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. Circulation 2003 0.75
38 Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization. Basic Clin Pharmacol Toxicol 2011 0.75
39 [Hormone replacement therapy in menopause and cardiovascular disease]. Ugeskr Laeger 2002 0.75
40 Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thromb Haemost 2006 0.75
41 Internal quality control of PCR-based genotyping methods: practical experiences. Vascul Pharmacol 2002 0.75
42 On the route to combined evidence from OC and HRT/ERT. Eur J Contracept Reprod Health Care 2002 0.75
43 Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke. Blood Coagul Fibrinolysis 2014 0.75
44 Application of the UK NHS Improvement Anticoagulation Commissioning Support Document for 'safety indicators' in atrial fibrillation. Results of the European Action on Anticoagulation study. J Clin Pathol 2012 0.75
45 Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women. Thromb Haemost 2017 0.75
46 Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo. Thromb Res 2011 0.75
47 INR derivation with the PT/INR Line simplified using a spreadsheet from the world wide web. J Clin Pathol 2011 0.75